Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
Cytokine ; 69(1): 110-5, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-25022969

RESUMEN

Anorexia nervosa (AN) is a serious, potentially life-threatening disorder characterized by severe weight loss, dysregulated eating, and often excessive exercise. While psychiatric illnesses such as depression are associated with increased levels of pro-inflammatory mediators, evidence for such disturbances in patients with AN has been less clear. In an exploratory study of possible disturbances in immune responses in AN, we assayed a panel of cytokines and chemokines in the blood of patients undergoing inpatient treatment, testing the hypothesis that metabolic disturbances in this disease would lead to a pattern of immune disturbances distinct from that of other psychiatric diseases. For this purpose, we evaluated patients by the Beck Depression Inventory-II (BDI-II) and the Eating Disorders Examination-Questionnaire and assessed cytokines and chemokines by enzyme-linked immunosorbent assays. Patients reported a moderate level of depression (mean BDI-II = 22.6) but exhibited few immunologic abnormalities of the kind associated with major depressive disorder [e.g., increased interleukin (IL)-6]; RANTES showed the most frequent elevations and was increased in 4 of the patients studied. Together, these findings suggest that features of AN such as loss of adipose tissue and excessive exercise may attenuate cytokine production and thus modulate the experience of illness that impacts on core features of disease.


Asunto(s)
Anorexia Nerviosa/sangre , Quimiocina CCL5/sangre , Depresión/complicaciones , Interleucina-6/sangre , Adolescente , Adulto , Composición Corporal , Quimiocina CCL5/biosíntesis , Ensayo de Inmunoadsorción Enzimática , Ejercicio Físico , Femenino , Humanos , Persona de Mediana Edad , Proyectos Piloto , Escalas de Valoración Psiquiátrica , Encuestas y Cuestionarios , Pérdida de Peso , Adulto Joven
2.
Autoimmun Rev ; 11(8): 572-6, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22037116

RESUMEN

Will vaccination raise the incidence of autoimmune diseases, what is the impact of increasingly crowded vaccination schedules, the vaccination in age groups and the risk of coincidental temporal association? All these issues are still under debate. However, for the time being, to avoid confusion in the medical community and the media, we have to adhere to guidelines established consensually by experts while ensuring a strict surveillance and reporting possible side effects. Recommendation for vaccination in patients with autoimmune inflammatory rheumatic diseases (AIIRD) based on the currently available evidence and expert opinion were recently formulated by an EULAR task force. Major recommendations for AIIRD include: i) vaccination should ideally be administered during stable disease; ii) influenza vaccination and pneumococcal vaccination should be strongly considered; iii) vaccination can be administered during the use of DMARDs and TNF-inhibitors, but before starting rituximab; iv) live attenuated vaccines should be avoided whenever possible in immunosuppressed patients; v) BCG vaccination is not recommended.


Asunto(s)
Artritis Reumatoide/tratamiento farmacológico , Artritis Reumatoide/inmunología , Autoinmunidad , Vacunación/efectos adversos , Animales , Artritis Reumatoide/complicaciones , Humanos , Inmunosupresores/uso terapéutico , Guías de Práctica Clínica como Asunto , Riesgo , Medición de Riesgo
3.
Clin Exp Rheumatol ; 27(1): 79-83, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19327233

RESUMEN

OBJECTIVE: To investigate lipid and apolipoprotein (Apo) levels in synovial fluid (SF) and serum of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and osteoarthritis (OA). METHODS: SF of 44 patients (14 RA, 14 PsA, 16 OA) was tested for Apo A-I, HDL-C, total cholesterol (TC), IL-1Beta, TNF-alpha, white blood cell count (WBC) and polymorphonucleate (PMN) percentage. Blood samples, collected simultaneously to the SF, were examined for Apo A-I, HDL-C, TC, TNF-alpha, serum amyloid A (SAA) and C-reactive protein (CRP). Thirty-three healthy donors served as a control group. RESULTS: Serum levels of Apo A-I, HDL-C and TC were higher in OA as compared with RA, PsA and the control group. The patients with inflammatory arthritis had lower serum levels of Apo A-I and HDL-C than did the controls. Apo A-I concentrations were higher in SF of RA patients, while PsA showed the highest concentration of TC, though not reaching statistical significance. A negative correlation was found between serum Apo A-I and synovial WBC (r=-0.48 p=0.002) and IL-1Beta (r=-0.42 p=0.016). There was a strong positive correlation between the Apo A-I SF/serum ratio and synovial WBC (r=0.73 p<0.001), IL-1Beta (r=0.68 p<0.001) and a weak, yet significant, correlation with serum CRP (r=0.49 p=0.002) and SAA (r=0.41 p=0.008). CONCLUSION: Our study confirms that in RA Apo A-I and TC levels are decreased in plasma and increased in SF, thus suggesting infiltration of HDL particles in the inflamed joint with inhibition of the local production of proinflammatory cytokines. On the other hand, it can be hypothesized that the sequestration of Apo A-I in the inflamed tissue may, in part, account for the reduction of circulating HDL and the excess cardiovascular risk in RA and PsA patients.


Asunto(s)
Apolipoproteína A-I/metabolismo , Artritis/metabolismo , Colesterol/metabolismo , Articulación de la Rodilla/metabolismo , Líquido Sinovial/metabolismo , Adulto , Anciano , Apolipoproteína A-I/sangre , Artritis/inmunología , Artritis Psoriásica/inmunología , Artritis Psoriásica/metabolismo , Proteína C-Reactiva/metabolismo , Colesterol/sangre , HDL-Colesterol/sangre , Estudios de Cohortes , Femenino , Humanos , Articulación de la Rodilla/inmunología , Masculino , Persona de Mediana Edad , Osteoartritis/inmunología , Osteoartritis/metabolismo , Líquido Sinovial/inmunología
4.
Lupus ; 18(3): 257-63, 2009 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-19213865

RESUMEN

Systemic lupus erythematosus (SLE) is a complex, multisystem autoimmune disorder, which often involves referral to multiple medical specialists. Lupus nephritis (LN) occurs in ~35% of adults with SLE and predicts poor survival. There is currently no consensus on how to manage patients with SLE or LN across specialties and across different European countries. The Lupus Nephritis Terminology Advisory Group was formed to address this issue as it impacts upon LN treatment. It has developed consensus statements based on opinions from expert panel meetings with nephrologists, nephropathologists, rheumatologists, clinical immunologists and internal medicine specialists from many European countries, after reviewing current guidelines from the European League Against Rheumatism, the American College of Rheumatology and the participants' experience. In this article, we report consensus statements that were developed in six important areas: classification of patients with LN, how classification affects the selection of treatment options and definitions of induction, response, flare and maintenance. We have also proposed a consensus for the terminology involved in the management of LN that is consistent with clinical opinion gathered from multidisciplinary expert meetings and with existing guidelines. We believe this consensus approach provides agreed expert opinion to clinicians and will form the basis for optimising LN treatment.


Asunto(s)
Nefritis Lúpica , Proyectos de Investigación/normas , Terminología como Asunto , Adulto , Europa (Continente) , Humanos , Nefritis Lúpica/clasificación , Nefritis Lúpica/fisiopatología , Nefritis Lúpica/terapia , Guías de Práctica Clínica como Asunto , Índice de Severidad de la Enfermedad , Sociedades Médicas
5.
Diabetes Metab ; 34(1): 75-81, 2008 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-18243027

RESUMEN

UNLABELLED: Adipose tissue secretes a variety of cytokines, some of which are increased in the serum of obese patients. The anti-inflammatory interleukin-1 receptor antagonist (IL-1Ra) is the most highly elevated known cytokine in human obesity, and its serum levels are strongly associated with the degree of insulin resistance in non-diabetic patients. AIM: The present study examined serum levels of IL-1Ra in type 2 diabetic patients (T2DM) and their relationships with three other adipokines (leptin, interleukin-6 [IL-6], adiponectin). Their correlation with anthropometric and biochemical variables was examined, as well as their intraindividual fluctuations. METHODS: Fifty T2DM patients, aged 58+/-13 years, were consecutively recruited among those electively hospitalized for a one-week intensive training course with our Diabetes Education Service. Anthropometric measurements and blood samples were taken after an overnight fast on admission (baseline) and after four days. RESULTS: Mean serum levels of IL-1Ra and leptin, but not of IL-6 and adiponectin, were significantly higher in women than in men (P<0.0006), and this difference persisted after correction for body mass index (BMI) (P<0.0004). In addition, IL-1Ra and leptin were strongly correlated with the BMI (P<0.0004). By contrast, no significant correlations were observed between IL-1Ra and glucose-control parameters. Finally, all four adipokines exhibited wide interindividual variability, but with limited intraindividual fluctuations over the short time period. CONCLUSION: IL-1Ra, leptin and adiponectin serum levels exhibit marked interindividual variation with high intraindividual consistency. A gender-based dimorphic pattern for IL-1Ra, independent of the degree of adiposity and glucose control, was also found.


Asunto(s)
Diabetes Mellitus Tipo 2/sangre , Proteína Antagonista del Receptor de Interleucina 1/sangre , Adiponectina/sangre , Adulto , Anciano , Anciano de 80 o más Años , Peso Corporal , Femenino , Hemoglobina Glucada/análisis , Humanos , Leptina/sangre , Masculino , Persona de Mediana Edad , Selección de Paciente , Caracteres Sexuales
6.
Rheumatology (Oxford) ; 46(12): 1779-85, 2007 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-17982166

RESUMEN

OBJECTIVES: Antibodies binding to the surface of fibroblasts (anti-fibroblast antibodies: AFA) have been described in systemic sclerosis (SSc). We aimed to assess the effect of AFA on extracellular matrix (ECM) turnover and whether AFA were associated with anti-topoisomerase-I antibody. METHODS: IgG were purified from AFA-positive and AFA-negative sera selected within 20 SSc and 20 healthy individuals, and tested on normal dermal fibroblasts, at protein and mRNA level, for their capacity to induce collagen deposition or degradation. RESULTS: Fibroblasts stimulated with AFA-positive but not with AFA-negative and control IgG showed an increased capacity to digest collagen matrix and produce metalloproteinase-1 (MMP-1) while their production of total collagen, type I collagen and tissue inhibitor of metalloproteinase-1 (TIMP-1) was unaffected. The steady-state mRNA levels of MMP-1, COL1A1 and TIMP-1 paralleled the protein levels. AFA-positive IgG did not induce Smad 2/3 phosphorylation, indicating that this transforming growth factor-beta signalling pathway was not involved. IL-1 and tumour necrosis factor (TNF) neutralization did not reverse the enhanced production of MMP-1, suggesting a direct effect of AFA on fibroblasts. Finally, anti-topoisomerase-I antibodies were present in 11 of 12 AFA-negative IgG, and an anti-topoisomerase-I monoclonal antibody failed to enhance MMP-1 production, thus indicating a lack of correlation between AFA and anti-topoisomerase-I antibody. CONCLUSIONS: These results indicate that SSc antibodies binding to fibroblasts enhance matrix degradation and MMP production events that may favour inflammation but do not directly impact on fibrosis development.


Asunto(s)
Anticuerpos Antiidiotipos/análisis , Colágeno/metabolismo , Metaloproteinasa 1 de la Matriz/metabolismo , Esclerodermia Sistémica/inmunología , Inhibidor Tisular de Metaloproteinasa-1/metabolismo , Adulto , Anticuerpos Antiidiotipos/efectos de los fármacos , Western Blotting , Estudios de Casos y Controles , Células Cultivadas , Ensayo de Inmunoadsorción Enzimática , Femenino , Fibroblastos/efectos de los fármacos , Fibroblastos/inmunología , Técnica del Anticuerpo Fluorescente Indirecta , Humanos , Inmunoglobulina G/farmacología , Interleucina-1/farmacología , Masculino , Metaloproteinasa 1 de la Matriz/efectos de los fármacos , Persona de Mediana Edad , ARN Mensajero/análisis , Esclerodermia Sistémica/fisiopatología , Piel/patología , Inhibidor Tisular de Metaloproteinasa-1/efectos de los fármacos
7.
Diabetologia ; 49(2): 387-93, 2006 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-16385385

RESUMEN

AIMS/HYPOTHESIS: The IL-1 receptor antagonist (IL-1Ra) is an anti-inflammatory cytokine known to antagonise the actions of IL-1. We have previously shown that IL-1Ra is markedly upregulated in the serum of obese patients, is correlated with BMI and insulin resistance, and is overexpressed in the white adipose tissue (WAT) of obese humans. The aim of this study was to examine the role of IL-1Ra in the regulation of glucose homeostasis in rodents. METHODS: We assessed the expression of genes related to IL-1 signalling in the WAT of mice fed a high-fat diet, as well as the effect of Il1rn (the gene for IL-1Ra) deletion and treatment with IL-1Ra on glucose homeostasis in rodents. RESULTS: We show that the expression of Il1rn and the gene encoding the inhibitory type II IL-1 receptor was upregulated in diet-induced obesity. The blood insulin:glucose ratio was significantly lower in Il1rn ( -/- )animals, which is compatible with an increased sensitivity to insulin, reinforced by the fact that the insulin content and pancreatic islet morphology of Il1rn ( -/- ) animals were normal. In contrast, the administration of IL-1Ra to normal rats for 5 days led to a decrease in the whole-body glucose disposal due to a selective decrease in muscle-specific glucose uptake. CONCLUSIONS/INTERPRETATION: The expression of genes encoding inhibitors of IL-1 signalling is upregulated in the WAT of mice with diet-induced obesity, and IL-1Ra reduces insulin sensitivity in rats through a muscle-specific decrease in glucose uptake. These results suggest that the markedly increased levels of IL-1Ra in human obesity might contribute to the development of insulin resistance.


Asunto(s)
Grasas de la Dieta/efectos adversos , Resistencia a la Insulina/fisiología , Insulina/fisiología , Obesidad/fisiopatología , Receptores de Interleucina-1/antagonistas & inhibidores , Sialoglicoproteínas/fisiología , Tejido Adiposo/fisiopatología , Animales , Glucemia/análisis , Eliminación de Gen , Regulación de la Expresión Génica , Técnica de Clampeo de la Glucosa , Insulina/sangre , Resistencia a la Insulina/genética , Proteína Antagonista del Receptor de Interleucina 1 , Interleucina-1/fisiología , Islotes Pancreáticos/química , Islotes Pancreáticos/patología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Músculo Esquelético/metabolismo , Obesidad/etiología , Obesidad/genética , ARN Mensajero/análisis , ARN Mensajero/genética , Receptores de Interleucina-1/genética , Receptores de Interleucina-1/fisiología , Receptores Tipo II de Interleucina-1 , Sialoglicoproteínas/genética , Sialoglicoproteínas/farmacología , Transducción de Señal , Regulación hacia Arriba
8.
Ann Rheum Dis ; 63(11): 1393-8, 2004 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-15479888

RESUMEN

OBJECTIVE: To measure synovial tissue interleukin-18 (IL-18) expression in patients with inflammatory arthritis, and to identify associations with serum levels, disease activity, and response to treatment. METHODS: Synovial tissue biopsies and serum samples were obtained from patients with early, active, rheumatoid arthritis (RA) (n = 12), undifferentiated seronegative arthritis (SnA) (n = 9), psoriatic arthritis (PsA) (n = 5), and reactive arthritis (ReA) (n = 2) before and one year after introduction of disease modifying antirheumatic drug (DMARD) treatment. Osteoarthritis (OA) tissues were compared. Tissue IL-18 expression was determined after immunohistochemical staining using a semiquantitative scale. Serum IL-18 was measured by enzyme linked immunosorbent assay. RESULTS: Before treatment was started, tissue IL-18 expression was increased in each diagnostic group compared with OA (p<0.05). Tissue IL-18 expression was correlated with serum C reactive protein levels (r = 0.53, p = 0.003) but not with serum IL-18. After DMARD treatment, 12 patients (five RA, four SnA, three PsA) were re-evaluated. Decreases in tissue IL-18 expression were observed in eight, although the trend did not reach significance (p = 0.068). Changes in tissue IL-18 expression were correlated with changes in serum IL-18 (r = 0.62, p = 0.041) and C reactive protein (r = 0.72, p = 0.009). CONCLUSIONS: Synovial tissue IL-18 expression was correlated with disease activity in inflammatory arthritis. After treatment, tissue levels changed in parallel with changes in serum IL-18 and with changes in the acute phase response. These observations support a role for IL-18 in the pathophysiology of inflammatory arthritis.


Asunto(s)
Antirreumáticos/uso terapéutico , Artritis/tratamiento farmacológico , Artritis/inmunología , Interleucina-18/análisis , Membrana Sinovial/inmunología , Enfermedad Aguda , Adulto , Artritis Psoriásica/inmunología , Artritis Reactiva/inmunología , Artritis Reumatoide/inmunología , Biomarcadores/análisis , Proteína C-Reactiva/análisis , Femenino , Humanos , Inmunohistoquímica/métodos , Interleucina-18/sangre , Masculino , Persona de Mediana Edad , Osteoartritis/inmunología , Prohibitinas , Estadísticas no Paramétricas
9.
Reumatismo ; 56(1 Suppl 1): 3-8, 2004.
Artículo en Italiano | MEDLINE | ID: mdl-15201935

RESUMEN

IL-1 and TNF-alpha are potent inducers of matrix metalloproteinases (MMP), eicosanoids, nitric oxide oxydase (iNOS), receptor activator of NF-kB ligand (RANKL), products involved in the destruction of the extracellular matrix, the cartilage and in bone resorption. IL-1, particularly important at the local level, is more potent than TNF-alpha in stimulating MMP and specifically in impeding cartilage repair. However, IL-1 and TNF-alpha strongly synergize in multiple biological functions. Blockade of IL-1 by IL-1 receptor antagonist (IL-1Ra, sIL-1RII) in combination with the soluble IL-1 accessory protein (IL-1R AcP) result in a long-term beneficial effect in chronic inflammatory diseases. The association with anti-TNF-alpha therapy may also represent a logical approach, considering the number of patients that do not respond to either compound alone.


Asunto(s)
Artritis Reumatoide/etiología , Interleucina-1/fisiología , Sialoglicoproteínas/fisiología , Animales , Humanos , Proteína Antagonista del Receptor de Interleucina 1 , Interleucina-1/antagonistas & inhibidores , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores
10.
Rheumatology (Oxford) ; 42(1): 89-96, 2003 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-12509619

RESUMEN

OBJECTIVES: To investigate the effects of the active metabolite of leflunomide, A77 1726, on fibroblast-like synoviocytes. In rheumatoid arthritis (RA) synoviocytes participate in tissue destruction by producing metalloproteinases (MMP), prostaglandin E(2) (PGE(2)) and interleukin (IL) 6, which are involved in extracellular matrix degradation, resorption of the mineral phase and osteoclast-mediated bone resorption. METHODS: Human synoviocytes were stimulated with IL-1alpha or tumour necrosis factor alpha (TNF-alpha) in the presence of A77 1726. Culture supernatants were analysed for production of interstitial collagenase (MMP-1), tissue-inhibitor of metalloproteinases 1 (TIMP-1), PGE(2) and IL-6. Total RNA was isolated and analysed for steady-state levels of MMP-1, cyclooxygenase-2 (COX-2) and IL-6 mRNA. RESULTS: A77 1726 inhibited the production of PGE(2) in synoviocytes activated by TNF-alpha and IL-1alpha with median inhibitory concentrations (IC(50)) of 7 and 3 microM respectively. In contrast, MMP-1 and IL-6 production was inhibited at high A77 1726 concentrations (> 10 microM), whereas TIMP-1 was not affected. The inhibition of MMP-1 and IL-6 production was due to the known inhibitory effect of A77 1726 on pyrimidine synthesis, as it was reversed by the addition of uridine. This did not apply to PGE(2) production, which was inhibited via direct action of A77 1726 on COX-2, as shown by the increasing amount of substrate (arachidonic acid) in the culture medium. CONCLUSION: This study shows that some of the beneficial effect of leflunomide in RA patients may be due to the inhibition of PGE(2), IL-6 and MMP-1 production in synoviocytes. This effect, coupled with its multiple inhibitory effects on T lymphocyte functions, might account for the significant reduction in the rate of disease progression in RA patients treated with leflunomide.


Asunto(s)
Compuestos de Anilina/farmacología , Antiinflamatorios no Esteroideos/farmacología , Artritis Reumatoide/metabolismo , Dinoprostona/antagonistas & inhibidores , Hidroxibutiratos/farmacología , Interleucina-6/antagonistas & inhibidores , Inhibidores de la Metaloproteinasa de la Matriz , Membrana Sinovial/metabolismo , Ácido Araquidónico/farmacología , Células Cultivadas , Crotonatos , Ciclooxigenasa 2 , Dinoprostona/genética , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/farmacología , Gliceraldehído-3-Fosfato Deshidrogenasas/metabolismo , Humanos , Interleucina-6/genética , Isoenzimas/metabolismo , Metaloproteinasa 1 de la Matriz/genética , Proteínas de la Membrana , Nitrilos , Prostaglandina-Endoperóxido Sintasas/metabolismo , Pirimidinas/metabolismo , ARN Mensajero/análisis , Membrana Sinovial/efectos de los fármacos , Toluidinas , Uridina/farmacología
11.
Ann Rheum Dis ; 61(8): 726-9, 2002 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-12117681

RESUMEN

OBJECTIVE: To measure serum interleukin 18 (IL18) and IL18 binding protein (IL18BP) levels in patients with inflammatory arthropathies, and to identify associations with disease status and the response to treatment. METHODS: Serum samples were obtained before and after methotrexate treatment from patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) attending an early arthritis clinic. IL18 and IL18BP were measured by enzyme linked immunosorbent assay (ELISA). RESULTS: Sixty patients with RA and 13 with PsA were evaluated. Serum IL18 levels were significantly higher in RA than in PsA (p<0.001). After six months' treatment with methotrexate, IL18 levels were reduced, but the differences were not significant (p=0.052). In cross sectional analyses, no correlations between IL18 levels and measures of disease activity or structural damage in RA were found. In longitudinal analyses, no correlations between IL18 levels and the response to treatment or the degree of progressive joint damage were found. Similarly, IL18BP levels were raised in RA, and were not associated with measures of the clinical status or the response to treatment. CONCLUSION: Raised serum levels of IL18 are consistent with a pathophysiological role in RA. However, in this study measurement of circulating IL18 and IL18BP did not correlate significantly with clinical measures of disease activity or the response to treatment in patients with early RA.


Asunto(s)
Antirreumáticos/uso terapéutico , Artritis Reumatoide/sangre , Glicoproteínas/sangre , Interleucina-18/sangre , Artritis Psoriásica/sangre , Artritis Reumatoide/tratamiento farmacológico , Ensayo de Inmunoadsorción Enzimática , Humanos , Péptidos y Proteínas de Señalización Intercelular , Metotrexato/uso terapéutico
12.
Matrix Biol ; 21(1): 103-10, 2002 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-11827797

RESUMEN

In tuberculosis, matrix metalloproteinase (MMP) secretion is involved in leukocyte migration to sites of infection but in excess may contribute to tissue destruction. We demonstrate that human monocytic THP-1 cells and primary monocytes secrete MMP-1 (52 kD collagenase) when phagocytosing live, virulent M. tuberculosis but not inert latex. The magnitude of MMP-1 secretion was approximately 10-fold less when compared to MMP-9 (92 kD gelatinase) secretion. MMP-1 secretion was also relatively delayed (detected at 24 h vs. 4 h). M. tuberculosis, zymosan or latex stimulate similar TIMP-1 secretion within 8 h and increasing over 24 h. MMP-1/9 secretion was decreased by inhibitors of protein kinase (PK) C, PKA or tyrosine kinases (PTK) in a concentration-dependent manner. In contrast, TIMP-1 secretion was not affected by PKC or PTK blockade and only somewhat reduced by high level PKA inhibition. In summary, M. tuberculosis-infected monocytes secrete MMP-1 at lower concentrations than MMP-9 and such MMP secretion is regulated by multiple upstream signalling pathways which do not control TIMP-1 secretion. Divergent effects of i on MMP and TIMP secretion from monocytes may be important in influencing matrix degradation in vivo.


Asunto(s)
Carbazoles , Metaloproteinasa 1 de la Matriz/metabolismo , Metaloproteinasa 9 de la Matriz/metabolismo , Monocitos/microbiología , Mycobacterium tuberculosis/fisiología , Inhibidor Tisular de Metaloproteinasa-1/metabolismo , Línea Celular , Proteínas Quinasas Dependientes de AMP Cíclico/antagonistas & inhibidores , Inhibidores Enzimáticos/farmacología , Genisteína/farmacología , Humanos , Indoles/farmacología , Monocitos/efectos de los fármacos , Monocitos/metabolismo , Naftalenos/farmacología , Proteína Quinasa C/antagonistas & inhibidores , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Pirroles/farmacología , Transducción de Señal/fisiología , Zimosan/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA